Pharmaceutical giant Pfizer announced robust fiscal third-quarter results, surpassing analyst expectations and subsequently raising its full-year financial guidance. This optimistic revision signals a pivotal shift in the company’s trajectory, largely propelled by the burgeoning demand for its recently launched and strategically acquired products, as it actively navigates a post-pandemic landscape marked by diminishing COVID-19 related revenues and impending patent expirations. The positive financial disclosures were accompanied by a significant leadership change, with Cecile Guegan formally stepping into the role of Chief Financial Officer.
Navigating the Post-Pandemic Landscape and Strategic Reorientation
Pfizer’s journey through 2026 has been closely scrutinized by investors and industry observers, particularly as the massive financial tailwinds from its COVID-19 vaccine, Comirnaty, and antiviral treatment, Paxlovid, began to wane significantly. The third quarter’s performance underscores a successful recalibration of the company’s growth engines away from its pandemic-era blockbusters. For the period, Pfizer’s COVID-19 product revenue was notably low, a trend CEO Albert Bourla highlighted as "positive news for us" during an exclusive interview with CNBC. Bourla elaborated, stating, "COVID revenues was an overhang on the performance of our stock because of the perception that it is volatile and it’s material to us. Actually, we’ve proven that we can make it irrelevant." He emphasized that the company’s ability to beat estimates and raise guidance, even in a period of minimal COVID-19 product contribution, validates its strategic pivot, attributing the $1.5 billion increase in outlook to the "overperformance of the other products."
Despite the reduced impact on current earnings, Pfizer reaffirmed its full-year COVID-19 product outlook at approximately $4 billion. CFO Cecile Guegan noted during the earnings call that the majority of these sales are anticipated in the fourth quarter, aligning with typical vaccination seasons. This strategic management of expectations surrounding COVID-19 product sales is crucial for providing clarity to the market, which has grappled with the inherent volatility of pandemic-related demand.
Elevated Financial Projections and Key Drivers
For the full fiscal year, Pfizer now anticipates revenue to range between $62 billion and $64 billion. This marks a notable increase from its previous forecast of $60.5 billion to $62.5 billion. While the lower end of this revised range still hovers around the $62.6 billion revenue reported in 2025, the upward adjustment reflects management’s confidence in its operational momentum. Concurrently, the company also lifted its full-year adjusted profit outlook, projecting earnings per share (EPS) of $2.95 to $3.05, up from the prior guidance of $2.80 to $3.00 per share.
This improved outlook is a direct result of the robust performance of Pfizer’s diversified portfolio. The company’s strategy, which includes aggressive investments in new product launches and significant acquisitions, is clearly yielding dividends. Sales from newly launched and acquired products contributed an impressive $3.8 billion in the third quarter alone, demonstrating a 32% operational growth. This category includes pivotal assets such as Padcev, a targeted cancer drug; Abrysvo, its newly introduced respiratory syncytial virus (RSV) vaccine; Prevnar 20, an enhanced pneumococcal shot; and Lorbrena, an oral lung cancer drug. These products are central to Pfizer’s long-term strategy to mitigate the looming "loss of exclusivity" (LOE) headwinds.
Addressing the Patent Cliff: A Proactive Stance
The pharmaceutical industry is inherently cyclical, with periods of patent protection followed by generic competition. Pfizer is on the cusp of facing a significant "patent cliff," with several of its long-standing revenue drivers approaching or entering periods of generic competition. This includes some of its most successful drugs, such as Lyrica (already off-patent in many markets), Ibrance, Xeljanz, and notably, the anticoagulant Eliquis, co-developed with Bristol Myers Squibb, which is expected to face generic entry in the coming years.
CEO Albert Bourla articulated this challenge and Pfizer’s proactive response, stating, "In addition to the revenues that they generate now, and they will continue generating so that we can overcome the patent, the loss of patent exclusivity, we are bringing pipeline that will perform even better in terms of growth." This statement underscores the strategic imperative behind Pfizer’s recent acquisitions and internal pipeline development – to build a robust portfolio of next-generation therapies capable of offsetting the anticipated revenue declines from drugs losing patent protection.
The third-quarter results provided early evidence of this strategy’s effectiveness. While Eliquis remains a powerhouse, generating $2.52 billion in sales, a 25% increase that comfortably beat analyst expectations of $2.40 billion, the focus is increasingly shifting to newer assets. Padcev, for instance, recorded $720 million in revenue, exceeding the $658 million analysts had projected, highlighting its growing market penetration in oncology.
Strategic Acquisitions and Growth Vectors
Pfizer’s "comeback story" is intricately linked to its strategic M&A activities and investments in high-growth therapeutic areas. Recognizing the need to diversify beyond COVID-19, the company has made bold moves to bolster its pipeline, particularly in oncology and the burgeoning obesity market.
A cornerstone of this strategy is the acquisition of Seagen for approximately $43 billion, announced earlier in the fiscal year. Seagen is a leader in antibody-drug conjugates (ADCs), a cutting-edge class of cancer therapies that deliver potent chemotherapy directly to cancer cells while sparing healthy tissue. This acquisition significantly enhances Pfizer’s oncology portfolio, positioning it as a dominant player in a rapidly evolving and highly lucrative segment of the pharmaceutical market. The integration of Seagen’s innovative platform and pipeline is expected to be a major growth driver for Pfizer in the latter half of the decade.

Beyond oncology, Pfizer has also placed a "big bet" on weight loss treatments, a therapeutic area witnessing unprecedented demand and innovation. The original article mentions this through its "acquisition of Metsera." While not a full corporate acquisition of a company named Metsera, this likely refers to strategic collaborations, licensing agreements, or significant internal investments aimed at developing novel therapies in the metabolic disease space. Pfizer has publicly committed to developing a portfolio of obesity treatments, including oral GLP-1 receptor agonists, to compete in a market currently dominated by Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. This strategic entry into the obesity market represents a significant growth vector with multi-billion dollar potential.
Commitment to Cost Efficiency
Complementing its growth initiatives, Pfizer is also aggressively pursuing operational efficiencies. In August, the company expanded its multiyear cost-cutting efforts, now targeting approximately $9.7 billion in net savings through 2029. This ambitious program is designed to offset the sharp declines in COVID-19 product sales and improve overall profitability by streamlining operations, optimizing manufacturing, and reducing administrative overhead. Such a substantial savings target underscores Pfizer’s commitment to maintaining robust margins even as its revenue mix shifts and it invests heavily in future growth.
Third Quarter Financial Deep Dive
For the third quarter, Pfizer reported total revenue of $16.58 billion. While this figure appeared relatively flat compared to the same period a year ago, it was significantly impacted by an operational decrease of $57 million, predominantly due to lower COVID-19 revenues, alongside a $15 million negative impact from foreign exchange fluctuations.
Despite the overall flat top-line, the underlying performance of key products was remarkably strong.
- Eliquis: The blood thinner continued its impressive run, generating $2.52 billion in sales, a 25% increase year-over-year, comfortably exceeding analyst estimates.
- Padcev: This targeted cancer drug posted $720 million in revenue, surpassing the $658 million analysts were expecting.
- New Launches: Sales of Pfizer’s newly launched and acquired products were a standout, contributing $3.8 billion and growing 32% operationally. Beyond Padcev, this category includes the RSV vaccine Abrysvo, which is making significant inroads in the preventative health market; Prevnar 20, the latest iteration of its successful pneumococcal vaccine franchise; and Lorbrena, which continues to gain market share in advanced lung cancer.
CFO Cecile Guegan emphasized the importance of these products, stating, "We continue to invest behind this group of products to mitigate [loss of exclusivity] headwinds over the next several years. In addition, this quarter’s performance demonstrates clear progress against our objective of returning to growth toward the end of the decade."
Even Pfizer’s COVID-19 products, despite steep year-over-year declines, managed to exceed modest analyst expectations for the quarter. The COVID-19 vaccine, Comirnaty, generated $808 million in sales, topping StreetAccount estimates of $770.4 million. Similarly, the antiviral pill, Paxlovid, booked $449 million in sales, coming in above the $394.1 million that analysts had projected. This overperformance, however slight, indicates better-than-expected demand or inventory management in a challenging market.
On the profitability front, Pfizer reported net income of $3.24 billion, or 56 cents per share, for the period. This compares to net income of $3.54 billion, or 62 cents per share, during the third quarter of 2025. Excluding certain one-time items, such as restructuring charges and costs associated with intangible assets, Pfizer posted adjusted earnings per share of 87 cents for the quarter, reflecting the underlying operational strength. The quarter included a one-time $650 million charge, or a negative impact of 10 cents per share, tied to the company’s licensing and collaboration agreement with Chinese cancer drugmaker Innovent Biologics, which impacted reported net income.
Leadership Transition: A New Financial Helm
The reporting of these results coincided with a significant transition in Pfizer’s executive leadership. Cecile Guegan officially assumed the role of Chief Financial Officer this month. Guegan brings two decades of diverse finance leadership experience within Pfizer, having served as interim CFO since August following the departure of Dave Denton. Denton left Pfizer to take on the same position at Nike. Guegan’s internal promotion ensures continuity in financial strategy during a critical period of portfolio transformation and strategic execution for the company. Her deep institutional knowledge and understanding of Pfizer’s complex global operations will be invaluable as the company navigates its ambitious growth and cost-saving objectives.
Broader Implications and Market Outlook
Pfizer’s third-quarter performance and revised outlook have largely been met with positive sentiment from the market. Analysts are increasingly focused on the sustainability of growth from the new and acquired product portfolio as the company moves further away from its COVID-19 peak. The results suggest that Pfizer’s strategic pivot is gaining traction, instilling greater confidence in its ability to generate meaningful revenue and profit growth in the coming years.
The emphasis on oncology, rare diseases, and metabolic disorders, coupled with aggressive cost management, positions Pfizer to withstand patent expirations and maintain its competitive edge in the highly dynamic pharmaceutical industry. The successful integration of acquired assets like Seagen and the effective execution of its pipeline strategy, particularly in the competitive obesity market, will be key determinants of its long-term success. While challenges remain, including intense competition and regulatory hurdles, Pfizer’s latest earnings report offers a compelling narrative of resilience and strategic foresight, reinforcing its commitment to returning to robust growth towards the end of the decade.
